936901-73-4

Basic information

• Product Name: 3-(8-broMo-1-chloroH-pyrrolo[1,2-a]pyrazin-6-yl)cyclobutanone
• Synonyms: 3-(8-broMo-1-chloroH-pyrrolo[1,2-a]pyrazin-6-yl)cyclobutanone;3-(1-bromo-8-chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutan-1-one;3-(1-Bromo-8-Chloroimidazo[1,5-A]Pyrazin-3-Yl)Cyclobutanone;3-(1-Bromo-8-Chloroimidazo[1,5-A]Pyrazin-3-Yl)Cyclobutanone(WXC04772)
• CAS NO: 936901-73-4
• Molecular Formula: C₁₀H₇BrClN₃O
• Molecular Weight: 300.53908
• EINECS: -0
• Mol File: 936901-73-4.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(8-broMo-1-chloroH-pyrrolo[1,2-a]pyrazin-6-yl)cyclobutanone(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(8-broMo-1-chloroH-pyrrolo[1,2-a]pyrazin-6-yl)cyclobutanone(936901-73-4)
• EPA Substance Registry System: 3-(8-broMo-1-chloroH-pyrrolo[1,2-a]pyrazin-6-yl)cyclobutanone(936901-73-4)

Safety Data

• Hazardous Substances Data: 936901-73-4(Hazardous Substances Data)

Usage

General Description

3-(8-bromo-1-chloroH-pyrrolo[1,2-a]pyrazin-6-yl)cyclobutanone is a chemical compound with a complex molecular structure. It contains a cyclobutanone ring fused to a pyrrolopyrazine ring system, with bromine and chlorine atoms attached to the pyrazine ring. 3-(8-broMo-1-chloroH-pyrrolo[1,2-a]pyrazin-6-yl)cyclobutanone is likely to possess a variety of biological activities due to its unique structure, and may have potential applications in medicinal chemistry and drug discovery. Its synthesis and characterization could provide valuable insights into the reactivity and properties of similar heterocyclic compounds.

Upstream product

• 23761-23-1 3-oxocyclobutanecarboxylic acid 
• 939412-84-7 N-[(2-chlorophenyl(methyl))]-3-oxocyclobutanecarboxamide 
• 939412-81-4 3-oxocyclobutanecarboxylic acid 2,5-dioxopyrrolidin-1-yl ester 
• 936901-72-3 3-(8-chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone 

Relevant articles and documents

CYCLOALKYLIDENE CARBOXYLIC ACIDS AND DERIVATIVES AS BTK INHIBITORS

The present invention relates to novel cycloalkylidene carboxylic acids and derivatives thereof useful as Bruton tyrosine kinase (BTK) inhibitors. The present disclosure also relates to processes for their preparation, pharmaceutical compositions containing one or more such compounds, and to the use of such compounds and pharmaceutical compositions for the treatment of disorders involving mediation of BTK in humans (Formula I).

Discovery of novel insulin-like growth factor-1 receptor inhibitors with unique time-dependent binding kinetics

This letter describes a series of small molecule inhibitors of IGF-1R with unique time-dependent binding kinetics and slow off-rates. Structure-activity and structure-kinetic relationships were elucidated and guided further optimizations within the series

Process to prepare substituted imidazopyrazine compounds

A method of preparing wherein, X=Cl, Br, I, comprises the step of treating with N-chloro-, N-bromo-, or N-iodosuccinimide in a compatible solvent such as dimethylformamide (DMF) at 0-60° C. followed by halogenation.